Bank of New York Mellon Corp Invests $190,000 in Maze Therapeutics, Inc. (NASDAQ:MAZE)

Key Points

• The Bank of New York Mellon Corp acquired 17,233 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE), valued at approximately $190,000, indicating growing interest from institutional investors.
• Research firms have rated Maze Therapeutics with multiple buy ratings, with an average target price of $25.60, reflecting a positive outlook for the company's stock performance.
• Maze Therapeutics reported earnings per share of ($1.15), which fell short of the consensus estimate, highlighting ongoing challenges despite a robust investment interest.

Bank of New York Mellon Corp purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 17,233 shares of the company's stock, valued at approximately $190,000.

Separately, General Catalyst Group Management LLC bought a new stake in Maze Therapeutics in the first quarter worth $11,405,000.

Maze Therapeutics Stock Down 6.5%

Shares of Maze Therapeutics stock traded down $0.93 during midday trading on Thursday, hitting $13.32. The company had a trading volume of 156,197 shares, compared to its average volume of 203,463. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $19.19. The business has a fifty day moving average price of $13.82.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.39).

Wall Street Analysts Forecast Growth

MAZE has been the topic of several recent analyst reports. Wedbush started coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They set an "outperform" rating and a $17.00 target price on the stock. HC Wainwright assumed coverage on shares of Maze Therapeutics in a research report on Wednesday, July 23rd. They set a "buy" rating and a $34.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $25.60.

Maze Therapeutics Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.